Loading...

You're on the old version of Simply Wall St. We will no longer be supporting this site, so we recommend you switch to our brand new platform.

Sol-Gel Technologies

Nasdaq:SLGL
Snowflake Description

Flawless balance sheet with high growth potential.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
SLGL
Nasdaq
$146M
Market Cap
  1. Home
  2. US
  3. Pharmaceuticals & Biotech
Company description

Sol-Gel Technologies Ltd., a clinical stage specialty pharmaceutical company, focuses on developing and commercializing topical dermatological drug products based on its proprietary microencapsulation delivery system in Israel. The last earnings update was 10 days ago. More info.


Add to Portfolio Compare Print
  • Sol-Gel Technologies has significant price volatility in the past 3 months.
SLGL Share Price and Events
7 Day Returns
-13.8%
NasdaqGM:SLGL
4.1%
US Pharmaceuticals
-4.1%
US Market
1 Year Returns
-8.4%
NasdaqGM:SLGL
-7%
US Pharmaceuticals
-14.9%
US Market
SLGL Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Sol-Gel Technologies (SLGL) -13.8% -37.8% -58.7% -8.4% - -
US Pharmaceuticals 4.1% -8.7% -12.1% -7% 4.7% 0.6%
US Market -4.1% -19.1% -23.4% -14.9% 3.5% 14.5%
1 Year Return vs Industry and Market
  • SLGL underperformed the Pharmaceuticals industry which returned -7% over the past year.
  • SLGL outperformed the Market in United States of America which returned -14.9% over the past year.
Price Volatility
SLGL
Industry
5yr Volatility vs Market

Value

 Is Sol-Gel Technologies undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of Sol-Gel Technologies to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for Sol-Gel Technologies.

NasdaqGM:SLGL Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 5 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 6.8%
Perpetual Growth Rate 10-Year US Government Bond Rate 1.7%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for NasdaqGM:SLGL
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year US Govt Bond Rate 1.7%
Equity Risk Premium S&P Global 6.3%
Pharmaceuticals Unlevered Beta Simply Wall St/ S&P Global 0.69
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 0.691 (1 + (1- 23%) (1.4%))
0.798
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
0.8
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 1.74% + (0.8 * 6.33%)
6.8%

Discounted Cash Flow Calculation for NasdaqGM:SLGL using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for Sol-Gel Technologies is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

Note: Free cash flow to equity valuations ignore the company's cash or debt.

NasdaqGM:SLGL DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (USD, Millions) Source Present Value
Discounted (@ 6.8%)
2020 -40.40 Analyst x1 -37.83
2021 -20.30 Analyst x1 -17.80
2022 -5.10 Analyst x1 -4.19
2023 21.80 Analyst x1 16.75
2024 42.80 Analyst x1 30.80
2025 60.91 Est @ 42.3% 41.03
2026 79.26 Est @ 30.13% 50.00
2027 96.39 Est @ 21.62% 56.93
2028 111.48 Est @ 15.65% 61.65
2029 124.28 Est @ 11.48% 64.34
Present value of next 10 years cash flows $261.00
NasdaqGM:SLGL DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2029 × (1 + g) ÷ (Discount Rate – g)
= $124.28 × (1 + 1.74%) ÷ (6.8% – 1.74%)
$2,496.80
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= $2,496.80 ÷ (1 + 6.8%)10
$1,292.73
NasdaqGM:SLGL Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= $261.00 + $1,292.73
$1,553.73
Equity Value per Share
(USD)
= Total value / Shares Outstanding
= $1,553.73 / 22.50
$69.06
NasdaqGM:SLGL Discount to Share Price
Calculation Result
Value per share (USD) From above. $69.06
Current discount Discount to share price of $6.47
= -1 x ($6.47 - $69.06) / $69.06
90.6%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

Current Discount
Amount off the current price Sol-Gel Technologies is available for.
Intrinsic value
>50%
Share price is $6.47 vs Future cash flow value of $69.06
Current Discount Checks
For Sol-Gel Technologies to be considered undervalued it must be available for at least 20% below the current price. Less than 40% is even better.
  • Sol-Gel Technologies's share price is below the future cash flow value, and at a moderate discount (> 20%).
  • Sol-Gel Technologies's share price is below the future cash flow value, and at a substantial discount (> 40%).
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Sol-Gel Technologies's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Sol-Gel Technologies's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
NasdaqGM:SLGL PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-12-31) in USD $-1.26
NasdaqGM:SLGL Share Price ** NasdaqGM (2020-04-02) in USD $6.47
United States of America Pharmaceuticals Industry PE Ratio Median Figure of 24 Publicly-Listed Pharmaceuticals Companies 19.88x
United States of America Market PE Ratio Median Figure of 2,944 Publicly-Listed Companies 12.5x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Sol-Gel Technologies.

NasdaqGM:SLGL PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqGM:SLGL Share Price ÷ EPS (both in USD)

= 6.47 ÷ -1.26

-5.14x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Sol-Gel Technologies is loss making, we can't compare its value to the US Pharmaceuticals industry average.
  • Sol-Gel Technologies is loss making, we can't compare the value of its earnings to the United States of America market.
Price based on expected Growth
Does Sol-Gel Technologies's expected growth come at a high price?
Raw Data
NasdaqGM:SLGL PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -5.14x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 5 Analysts
53.6%per year
United States of America Pharmaceuticals Industry PEG Ratio Median Figure of 21 Publicly-Listed Pharmaceuticals Companies 1.88x
United States of America Market PEG Ratio Median Figure of 2,008 Publicly-Listed Companies 0.91x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Sol-Gel Technologies, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Sol-Gel Technologies's assets?
Raw Data
NasdaqGM:SLGL PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-12-31) in USD $2.57
NasdaqGM:SLGL Share Price * NasdaqGM (2020-04-02) in USD $6.47
United States of America Pharmaceuticals Industry PB Ratio Median Figure of 183 Publicly-Listed Pharmaceuticals Companies 2.41x
United States of America Market PB Ratio Median Figure of 5,142 Publicly-Listed Companies 1.22x
NasdaqGM:SLGL PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqGM:SLGL Share Price ÷ Book Value per Share (both in USD)

= 6.47 ÷ 2.57

2.52x

* Primary Listing of Sol-Gel Technologies.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Sol-Gel Technologies is overvalued based on assets compared to the US Pharmaceuticals industry average.
X
Value checks
We assess Sol-Gel Technologies's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Pharmaceuticals industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Pharmaceuticals industry average (and greater than 0)? (1 check)
  5. Sol-Gel Technologies has a total score of 2/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Sol-Gel Technologies expected to perform in the next 1 to 3 years based on estimates from 5 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
53.6%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Sol-Gel Technologies expected to grow at an attractive rate?
  • Sol-Gel Technologies's earnings growth is expected to exceed the low risk savings rate of 1.7%.
Growth vs Market Checks
  • Sol-Gel Technologies's earnings growth is expected to exceed the United States of America market average.
  • Sol-Gel Technologies's revenue growth is expected to exceed the United States of America market average.
Annual Growth Rates Comparison
Raw Data
NasdaqGM:SLGL Future Growth Rates Data Sources
Data Point Source Value (per year)
NasdaqGM:SLGL Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 5 Analysts 53.6%
NasdaqGM:SLGL Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 5 Analysts 39.6%
United States of America Pharmaceuticals Industry Earnings Growth Rate Market Cap Weighted Average 27.3%
United States of America Pharmaceuticals Industry Revenue Growth Rate Market Cap Weighted Average 5.1%
United States of America Market Earnings Growth Rate Market Cap Weighted Average 12.2%
United States of America Market Revenue Growth Rate Market Cap Weighted Average 7.1%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
NasdaqGM:SLGL Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 5 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
NasdaqGM:SLGL Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2024-12-31 179 44 48 3
2023-12-31 133 23 22 3
2022-12-31 111 -4 -8 4
2021-12-31 43 -19 -33 5
2020-12-31 13 -39 -40 3
2020-04-03
NasdaqGM:SLGL Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2019-12-31 23 -23 -25
2019-09-30 19 -30
2019-06-30 14 -28 -30
2019-03-31 6 -32
2018-12-31 0 -23 -32
2018-09-30 0 -26
2018-06-30 0 -21 -32
2018-03-31 0 -32
2017-12-31 0 -24 -32
2017-09-30 -22 -31
2017-06-30 -22 -24
2017-03-31 -22

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Sol-Gel Technologies's earnings are expected to grow significantly at over 20% yearly.
  • Sol-Gel Technologies's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
NasdaqGM:SLGL Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 5 Analyst Estimates (S&P Global) See Below

All data from Sol-Gel Technologies Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqGM:SLGL Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2024-12-31 1.79 2.04 1.51 3.00
2023-12-31 0.85 1.26 0.24 3.00
2022-12-31 -0.26 0.10 -0.78 3.00
2021-12-31 -1.25 -0.75 -1.60 4.00
2020-12-31 -1.75 -1.71 -1.79 3.00
2020-04-03
NasdaqGM:SLGL Past Financials Data
Date (Data in USD Millions) EPS *
2019-12-31 -1.26
2019-09-30 -1.56
2019-06-30 -1.59
2019-03-31 -1.70
2018-12-31 -1.80
2018-09-30 -1.75
2018-06-30 -2.81
2018-03-31 -3.79
2017-12-31 -5.02
2017-09-30 -4.93
2017-06-30 -3.83
2017-03-31 -3.52

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Sol-Gel Technologies will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess Sol-Gel Technologies's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the United States of America market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the United States of America market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Sol-Gel Technologies has a total score of 5/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Sol-Gel Technologies performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Sol-Gel Technologies's growth in the last year to its industry (Pharmaceuticals).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Sol-Gel Technologies does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Sol-Gel Technologies's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Sol-Gel Technologies's 1-year growth to the US Pharmaceuticals industry average as it is not currently profitable.
Earnings and Revenue History
Sol-Gel Technologies's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Sol-Gel Technologies Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqGM:SLGL Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-12-31 22.90 -24.61 8.28
2019-09-30 18.88 -29.88 7.35
2019-06-30 14.19 -30.24 6.18
2019-03-31 6.44 -32.22 6.06 6.15
2018-12-31 0.13 -32.20 5.50
2018-09-30 0.31 -25.78 5.20 21.96
2018-06-30 0.27 -32.36 6.20 16.43
2018-03-31 0.22 -31.65 6.53 25.43
2017-12-31 0.17 -31.57 6.00
2017-09-30 -30.98 5.71 25.32
2017-06-30 -24.09 4.47 19.60
2017-03-31 -22.15 3.48 18.64
2016-12-31 -20.77 3.73 17.02
2015-12-31 -9.66 2.46 7.18
2014-12-31 -4.85 1.88 2.93

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Sol-Gel Technologies has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Sol-Gel Technologies has efficiently used its assets last year compared to the US Pharmaceuticals industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Sol-Gel Technologies improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Sol-Gel Technologies's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Pharmaceuticals industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Sol-Gel Technologies has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Sol-Gel Technologies's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Sol-Gel Technologies's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Sol-Gel Technologies is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Sol-Gel Technologies's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Sol-Gel Technologies's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Sol-Gel Technologies has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Sol-Gel Technologies Company Filings, last reported 3 months ago.

NasdaqGM:SLGL Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-12-31 52.47 0.00 50.38
2019-09-30 58.57 0.00 57.73
2019-06-30 54.74 0.00 49.91
2019-03-31 58.97 0.00 54.43
2018-12-31 63.91 0.00 62.99
2018-09-30 74.91 0.00 73.47
2018-06-30 81.55 0.00 78.65
2018-03-31 87.04 0.00 83.80
2017-12-31 -52.70 65.34 9.02
2017-09-30 -48.99 65.34 16.49
2017-06-30 -42.78 65.34 23.30
2017-03-31 -31.34 37.34 7.00
2016-12-31 -31.34 37.34 7.00
2015-12-31 -11.52 17.34 5.90
2014-12-31 -2.99 3.34 0.59
  • Sol-Gel Technologies has no debt.
  • Sol-Gel Technologies currently has no debt however we can't compare to 5 years ago as we have no data for that period.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Sol-Gel Technologies has sufficient cash runway for 2.2 years based on current free cash flow.
  • Sol-Gel Technologies has sufficient cash runway for 1.5 years if free cash flow continues to grow at historical rates of 21.1% each year.
X
Financial health checks
We assess Sol-Gel Technologies's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Sol-Gel Technologies has a total score of 6/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Sol-Gel Technologies's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Sol-Gel Technologies dividends.
If you bought $2,000 of Sol-Gel Technologies shares you are expected to receive $0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Sol-Gel Technologies's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Sol-Gel Technologies's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
NasdaqGM:SLGL Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 5 Analyst Estimates (S&P Global) See Below
United States of America Pharmaceuticals Industry Average Dividend Yield Market Cap Weighted Average of 11 Stocks 3%
United States of America Market Average Dividend Yield Market Cap Weighted Average of 1941 Stocks 3.1%
United States of America Minimum Threshold Dividend Yield 10th Percentile 1.1%
United States of America Bottom 25% Dividend Yield 25th Percentile 2%
United States of America Top 25% Dividend Yield 75th Percentile 5.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

NasdaqGM:SLGL Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2024-12-31
2023-12-31
2022-12-31
2021-12-31
2020-12-31
2020-04-03

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Sol-Gel Technologies has not reported any payouts.
  • Unable to verify if Sol-Gel Technologies's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Sol-Gel Technologies's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Sol-Gel Technologies has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Sol-Gel Technologies's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1.1%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Sol-Gel Technologies afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Sol-Gel Technologies has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Sol-Gel Technologies's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Alon Seri-Levy
COMPENSATION $1,306,000
AGE 58
TENURE AS CEO 23.3 years
CEO Bio

Dr. Alon Seri-Levy is a Co-Founder at Sol-Gel Technologies Ltd. in 1997 and has been its Chief Executive Officer since 1997. Dr. Seri-Levy established the computer-aided drug design department at Peptor Ltd. Dr. Seri-Levy is a co-inventor of Sol-Gel Ltd.'s encapsulation technology. He also served as Director of Sol-Gel Technologies Ltd until 2014 and again joined as Director of Sol-Gel Technologies Ltd immediately following the pricing of the company's initial public offering in January 2018. Dr. Seri-Levy received his Ph.D. in chemistry summa cum laude from The Hebrew University of Jerusalem and did his post-graduate studies at the University of Oxford.

CEO Compensation
  • Alon's compensation has increased whilst company is loss making.
  • Alon's remuneration is higher than average for companies of similar size in United States of America.
Management Team Tenure

Average tenure and age of the Sol-Gel Technologies management team in years:

3.6
Average Tenure
49
Average Age
  • The tenure for the Sol-Gel Technologies management team is about average.
Management Team

Alon Seri-Levy

TITLE
Co-Founder
COMPENSATION
$1M
AGE
58
TENURE
23.3 yrs

Gilad Mamlok

TITLE
Chief Financial Officer
COMPENSATION
$1M
AGE
51
TENURE
3.1 yrs

Itzik Yosef

TITLE
Vice President of Operations
COMPENSATION
$290K
AGE
43
TENURE
3.7 yrs

David Avnir

TITLE
Co-Founder
TENURE
23.3 yrs

Karine Neimann

TITLE
VP of Projects & Planning and Chief Chemist
AGE
48
TENURE
3.6 yrs

John Vieira

TITLE
U.S. Head of Commercialization
AGE
49
TENURE
1.3 yrs
Board of Directors Tenure

Average tenure and age of the Sol-Gel Technologies board of directors in years:

2.3
Average Tenure
59
Average Age
  • The average tenure for the Sol-Gel Technologies board of directors is less than 3 years, this suggests a new board.
Board of Directors

Mori Arkin

TITLE
Chairman of the Board
AGE
66

Alon Seri-Levy

TITLE
Co-Founder
COMPENSATION
$1M
AGE
58
TENURE
2.3 yrs

Ran Gottfried

TITLE
External Director
AGE
75
TENURE
2.3 yrs

Jerrold Gattegno

TITLE
External Director
AGE
67
TENURE
2.3 yrs

Itai Arkin

TITLE
Director
AGE
31

Muli Ben-Zvi

TITLE
Independent Director
AGE
59
TENURE
2.3 yrs

Hani Lerman

TITLE
Director
AGE
46
TENURE
2.3 yrs

Yaffa Krindel

TITLE
Independent Director
AGE
64
TENURE
2.2 yrs

Jonathan Siegel

TITLE
Independent Director
AGE
45
TENURE
1.6 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month open market individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price ($) Value ($)
X
Management checks
We assess Sol-Gel Technologies's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Sol-Gel Technologies has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

What Percentage Of Sol-Gel Technologies Ltd. (NASDAQ:SLGL) Shares Do Insiders Own?

Sol-Gel Technologies is a smaller company with a market capitalization of US$164m, so it may still be flying under the radar of many institutional investors. … Our analysis of the ownership of the company, below, shows that institutional investors have bought into the company. … View our latest analysis for Sol-Gel Technologies NasdaqGM:SLGL Ownership Summary, August 13th 2019 What Does The Institutional Ownership Tell Us About Sol-Gel Technologies?

Simply Wall St -

Sol-Gel Technologies (NASDAQ:SLGL) Shareholders Booked A 11% Gain In The Last Year

See our latest analysis for Sol-Gel Technologies Given that Sol-Gel Technologies didn't make a profit in the last twelve months, we'll focus on revenue growth to form a quick view of its business development. … In the last year Sol-Gel Technologies saw its revenue grow by 2856%. … This free report showing analyst forecasts should help you form a view on Sol-Gel Technologies A Different Perspective Sol-Gel Technologies boasts a total shareholder return of 11% for the last year.

Simply Wall St -

Estimating The Fair Value Of Sol-Gel Technologies Ltd. (NASDAQ:SLGL)

by estimating the company's future cash flows and discounting them to their present value. … Discounted Cash Flows (DCF). … If you want to learn more about discounted cash flow, the basis for my calcs can be read in detail in the Simply Wall St analysis model

Simply Wall St -

Could Sol-Gel Technologies Ltd.'s (NASDAQ:SLGL) Investor Composition Influence The Stock Price?

With a market capitalization of US$120m, Sol-Gel Technologies is a small cap stock, so it might not be well known by many institutional investors. … Our analysis of the ownership of the company, below, shows that. … View our latest analysis for Sol-Gel Technologies

Simply Wall St -

Sol-Gel Technologies Ltd (NASDAQ:SLGL): Is Healthcare An Attractive Sector Play?

is a healthcare company operating in an industry,. … Pharma companies, in particular, are operating in a difficult environment prompted by a more challenging healthcare agenda … The global need for innovative, cost-effective medicines continues to rise, whilst regulators and healthcare providers require more transparency and proven effectiveness

Simply Wall St -

Why Sol-Gel Technologies Ltd's (NASDAQ:SLGL) Investor Composition Impacts Your Returns

In this analysis, my focus will be on developing a perspective on Sol-Gel Technologies Ltd’s (NASDAQ:SLGL) latest ownership structure, a less discussed, but important factor. … A company's ownership structure is often linked to its share performance in both the long- and short-term. … See our latest analysis for Sol-Gel Technologies

Simply Wall St -

What Should We Expect From Sol-Gel Technologies Ltd's (NASDAQ:SLGL) Earnings In The Years Ahead?

The latest earnings announcement Sol-Gel Technologies Ltd's (NASDAQ:SLGL) released in December 2017 indicated company earnings became less negative compared to the previous year's level as a result of recent tailwinds Today I want to provide a brief commentary on how market analysts perceive Sol-Gel Technologies's earnings growth trajectory over the next couple of years and whether the future looks brighter. … Check out our latest analysis for Sol-Gel Technologies Analysts' expectations for the upcoming year seems pessimistic, with earnings becoming even more negative, generating -US$43.50M in 2019. … The benefit of this technique is that it ignores near term flucuations and accounts for the overarching direction of Sol-Gel Technologies's earnings trajectory over time, be more volatile.

Simply Wall St -

Should You Be Concerned About Sol-Gel Technologies Ltd's (NASDAQ:SLGL) Shareholders?

Today, I will be analyzing Sol-Gel Technologies Ltd’s (NASDAQ:SLGL) recent ownership structure, an important but not-so-popular subject among individual investors. … Check out our latest analysis for Sol-Gel Technologies NasdaqGM:SLGL Ownership_summary Feb 13th 18 Insider Ownership Insiders form another group of important ownership types as they manage the company's operations and decide the best use of capital. … General Public Ownership The general public holds a substantial 34.75% stake in SLGL, making it a highly popular stock among retail investors.

Simply Wall St -

Is Sol-Gel Technologies Ltd (NASDAQ:SLGL) On The Right Side Of Disruption?

Check out our latest analysis for Sol-Gel Technologies What’s the catalyst for Sol-Gel Technologies's sector growth? … In the past year, the industry delivered growth of 6.23%, though still underperforming the wider US stock market. … A loose alternative to gauge Sol-Gel Technologies’s value is to assume the stock should be relatively in-line with its industry.

Simply Wall St -

Company Info

Description

Sol-Gel Technologies Ltd., a clinical stage specialty pharmaceutical company, focuses on developing and commercializing topical dermatological drug products based on its proprietary microencapsulation delivery system in Israel. The company’s lead product candidates include TWIN, which has completed Phase II clinical trials for the treatment of acne vulgaris; and Epsolay that has completed Phase II clinical trials for the treatment of papulopustular rosacea. It is also involved in the development of generic topical dermatological drug products. Sol-Gel Technologies Ltd. has collaboration with Perrigo; and Douglas Pharmaceuticals for the development and commercialization of a generic product candidate. The company was founded in 1997 and is headquartered in Ness Ziona, Israel.

Details
Name: Sol-Gel Technologies Ltd.
SLGL
Exchange: NasdaqGM
Founded: 1997
$145,569,532
22,499,155
Website: http://www.sol-gel.com
Address: Sol-Gel Technologies Ltd.
7 Golda Meir Street,
Weizmann Science Park,
Ness Ziona,
7403650,
Israel
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqGM SLGL Ordinary Shares Nasdaq Global Market US USD 01. Feb 2018
DB 4SG Ordinary Shares Deutsche Boerse AG DE EUR 01. Feb 2018
Number of employees
Current staff
Staff numbers
61
Sol-Gel Technologies employees.
Industry
Pharmaceuticals
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2020/04/03 06:43
End of day share price update: 2020/04/02 00:00
Last estimates confirmation: 2020/03/26
Last earnings filing: 2020/03/24
Last earnings reported: 2019/12/31
Last annual earnings reported: 2019/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.